Evotec And Claris Ventures Streamline Access to Accelerate Programmes from Claris's Portfolio Companies into The Clinic [Yahoo! Finance]
Evotec SE (EVO)
NASDAQ:AMEX Investor Relations:
eatonvance.com
Company Research
Source: Yahoo! Finance
AGREEMENT BUILDS ON SUCCESSFUL COLLABORATION BETWEEN EVOTEC AND CLARIS'S PORTFOLIO COMPANY IAMA HAMBURG, GERMANY / TURIN, ITALY / ACCESSWIRE / March 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) and biotech venture capital firm Claris Ventures ("Claris") today announced an acceleration framework to streamline programmes from Claris's portfolio companies into the clinic through Evotec's fully integrated platform. Claris's portfolio is focused on biotech companies with programmes approaching clinical trials and currently consists of nine biotech companies across Italy, Switzerland, and the UK. Claris provides resources, capabilities, and connections to complete pre-clinical studies and run first-in-human ("FIH") trials. Evotec is already supporting Claris's portfolio company IAMA Therapeutics ("IAMA"), a Genoese Biotech company focused on innovative medicines for brain disorders. Evotec has provided IAMA with pre-clinical services
Show less
Read more
Impact Snapshot
Event Time:
EVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVO alerts
High impacting Evotec SE news events
Weekly update
A roundup of the hottest topics
EVO
News
- Bayer and Evotec Collaborate to Advance Precision Cardiology [Yahoo! Finance]Yahoo! Finance
- Bayer and Evotec Collaborate to Advance Precision CardiologyAccesswire
- Evotec SE (NASDAQ:EVO) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Evotec SE (NASDAQ: EVO) had its price target lowered by analysts at HC Wainwright from $14.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Evotec: Still A Speculative Buy After A Significant Decline [Seeking Alpha]Seeking Alpha